PDRN
Polydeoxyribonucleotide, polynucleotide (PN), 'salmon DNA'
PDRN (Polydeoxyribonucleotide, polynucleotide (PN), 'salmon DNA') is a healing & recovery research compound. A mixture of purified DNA fragments (roughly 50–1,500 kDa) extracted from salmon or trout milt. Two mechanisms run in parallel, which is why it does more than a moisturizer. (1) Adenosine A2A receptor agonism — the fragments release adenosine-like signals that activate A2A, which upregulates VEGF, drives angiogenesis, and pushes macrophages from a pro-inflammatory toward a repair phenotype. (2) The salvage pathway — proliferating fibroblasts need purines and pyrimidines to build new DNA, and PDRN supplies them ready-made, so the cell spends less energy synthesizing nucleotides from scratch. The net result is fibroblast proliferation and collagen synthesis in tissue that is trying to rebuild.
PDRN quick facts
| Reported research dose (Injectable) | Injectable: 5.625mg per ampoule (clinical) · Topical: as directed |
| Route | Intradermal / subq (clinical) or topical |
| Frequency | Topical daily; injectable every 2-4 weeks |
| Half-life | Local depot; acts at the injection site rather than systemically |
| Forms | Injectable, Topical |
| Evidence level | Human RCTs for wound healing and diabetic foot ulcers; licensed as Placentex in Italy and widely used in Korean aesthetic practice |
| Other forms available | Topical — dosed differently |
The best-evidenced thing in the cosmetics section, and the gap between its two uses is large. Injected PDRN for wound healing has genuine randomized human data and regulatory approval in some countries. Topical PDRN is a much weaker proposition for one boring physical reason: DNA fragments of 50–1,500 kDa are enormous compared with what crosses an intact stratum corneum, so a serum cannot deliver what an injection does. That does not make a topical worthless — the formulations pair it with humectants and the skin feel is real — but do not read the injectable literature and assume it applies to a cream. Also note injectable PDRN is a regulated medical product in many places.
How PDRN works
A mixture of purified DNA fragments (roughly 50–1,500 kDa) extracted from salmon or trout milt. Two mechanisms run in parallel, which is why it does more than a moisturizer. (1) Adenosine A2A receptor agonism — the fragments release adenosine-like signals that activate A2A, which upregulates VEGF, drives angiogenesis, and pushes macrophages from a pro-inflammatory toward a repair phenotype. (2) The salvage pathway — proliferating fibroblasts need purines and pyrimidines to build new DNA, and PDRN supplies them ready-made, so the cell spends less energy synthesizing nucleotides from scratch. The net result is fibroblast proliferation and collagen synthesis in tissue that is trying to rebuild.
Proposed benefits
Wound healing, skin quality and hydration, post-procedure recovery, and tissue repair where blood supply is poor.
Where to get PDRN
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for PDRN
Graded by what exists behind each claim.
✅ Clinically validated
- Randomized human trials support injected PDRN for wound healing, most solidly in diabetic foot ulcers, where trials report faster and more complete closure against standard care. It is licensed as a medical product in Italy (Placentex) and used routinely in Korean clinical and aesthetic practice, which is a genuinely higher bar than most of this catalog clears.
- The aesthetic evidence is thinner than the wound-healing evidence, and the two get quoted interchangeably. Skin-quality studies are typically small, short, industry-adjacent and use operator-scored photographs. That the wound literature is strong does not transfer automatically to 'glass skin' claims.
📊 Correlative data
- Very widely used in Korean aesthetic practice as an injected 'skin booster', usually a course of three to six sessions. The consistency of practitioner reports across a large volume of procedures is meaningful, even though it is not controlled data.
- Topical PDRN serums are now everywhere in skincare. Reported experience is of hydration and post-procedure comfort rather than the remodeling seen with injection — which is exactly what the delivery physics would predict.
🧪 Theoretical / extrapolated
- Two mechanisms working together. Adenosine A2A receptor agonism drives VEGF expression and angiogenesis and shifts macrophages toward a repair phenotype; the salvage pathway supplies ready-made purines and pyrimidines so proliferating fibroblasts spend less energy building nucleotides from scratch.
- The delivery ceiling is the thing to understand before buying a serum. PDRN is a mixture of DNA fragments of roughly 50–1,500 kDa. Intact skin admits very little above about 0.5 kDa. An injection places the material where fibroblasts are; a cream largely cannot. This is not a criticism of any particular product — it is the reason the injected and topical literatures do not say the same thing, and why they should not be read as if they do.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What PDRN actually does
Start with the thing that makes PDRN unlike everything else in this Vault: it is not a molecule. It is a polydisperse mixture of DNA fragments, roughly 50 to 1,500 kDa, extracted and purified from the sperm cells of salmon or trout Kim 2021. There is no structure to draw, no molecular weight to quote, no receptor-binding constant for "PDRN" as such. A certificate of analysis can report DNA content, fragment size distribution and protein contamination — and that is the complete specification. Two ampoules meeting the same spec are not the same substance in the way two ampoules of a peptide are.
Mechanism one: adenosine A2A receptor agonism, and it is the well-supported one. Extracellular nucleases degrade the DNA fragments to nucleotides and then to nucleosides, releasing adenosine at the site. Adenosine acting at the A2A receptor raises intracellular cyclic AMP, which produces three things simultaneously: increased VEGF expression and angiogenesis, suppression of TNF-alpha and other pro-inflammatory cytokines, and increased collagen deposition by fibroblasts Galeano 2021. That is a coherent single-receptor explanation for an anti-inflammatory, pro-angiogenic, pro-collagen effect, and the A2A dependence has been demonstrated by blocking the receptor and losing the effect.
Mechanism two: the salvage pathway, which is a supply argument rather than a signaling one. Cells building DNA can either synthesize purines and pyrimidines from scratch — expensive, several ATP per base — or recycle nucleosides through the salvage pathway, which is far cheaper. PDRN delivers a local bolus of exactly those nucleosides Kim 2021. In a wound where fibroblasts are dividing rapidly under poor perfusion, that is plausibly rate-relevant; in healthy, well-fed tissue it is probably not, and the two mechanisms therefore predict quite different responders — the receptor mechanism should work anywhere, the salvage mechanism only where supply is limiting.
Why the source species is a real question and not squeamishness. Salmonid DNA is used because its base composition is close enough to human to be biologically compatible and because milt is an abundant, cheap source of high-molecular-weight DNA. The purification has to remove protein and peptide contaminants, since those are what would drive an immune response; the DNA itself is described as non-antigenic in this context. The safety of the product therefore depends on a purification step rather than on the active ingredient, which is an unusual place for the risk to sit.
One more mechanistic detail with a practical edge. Unmethylated CpG motifs in bacterial and viral DNA are the ligand for TLR9 and are strongly immunostimulatory. Vertebrate DNA is CpG-poor and methylated, which is why fish DNA does not behave like a TLR9 agonist — but it is also why the manufacturing source matters, and why bacterial contamination of a DNA product is not a trivial impurity.
Cell, rodent, human — and where it stops
Step one, in cells and in animals: consistent and mechanism-linked. Galeano 2021 collects the preclinical wound-healing work — A2A-dependent increases in VEGF, angiogenesis and granulation tissue, reductions in inflammatory cytokines, across several impaired-healing models including diabetic and ischemic wounds. Lim 2021 takes it into a different tissue entirely, testing bone regeneration in ceramic scaffolds across variable concentrations of PDRN and rhBMP-2 — a dose-ranging design in a hard-tissue model.
Step two, in humans, and the clinical literature is real but narrow. Araco 2023 is a prospective randomized exploratory study of highly purified polynucleotides with cross-linked hyaluronic acid for moderate to severe nasolabial folds — an aesthetic endpoint, a combination product, and explicitly exploratory. The injectable PDRN product licensed in Italy and used across Europe and Asia has a long clinical history in wound care and intra-articular use.
The obstacles, named one at a time.
(1) Most human studies test a combination. Araco 2023 pairs polynucleotides with cross-linked hyaluronic acid; the aesthetic literature generally does. Hyaluronic acid is a volumizing filler with its own visible effect, so a study of the pair cannot attribute the result to the nucleotides.
(2) Injecting anything into skin produces an effect. Needling alone triggers a wound-healing response and neocollagenesis — that is the entire basis of microneedling as a treatment. A trial without a saline-injection control cannot separate the drug from the needle, and this is the single largest methodological problem in the aesthetic PDRN literature.
(3) The product is not standardized across the market. The licensed European product is specified and manufactured to a pharmaceutical standard. "PDRN" and "polynucleotide" products sold elsewhere vary in source, fragment size and purity, and the clinical evidence does not transfer between them Kim 2021.
(4) Systemic pharmacokinetics essentially do not exist and arguably cannot. The card correctly describes a local depot. There is no meaningful plasma measurement for a mixture that is degraded to endogenous nucleosides at the injection site — you would be measuring the body's own adenosine pool.
What would have to be true, and how you would know it was not
This is a locally acting product, so the honest falsification test is mostly about the tissue rather than about blood. Both are here.
What to watch. For a wound or an ulcer: the measured area of the wound, photographed against a ruler on the same schedule, and the depth of granulation tissue. For skin: skin thickness or elasticity by instrument, not appearance, photographed under fixed lighting. For a joint: a validated pain and function score and range of motion, recorded before the first injection. The endpoint has to be written down before the first dose, because this compound is used in settings where things improve on their own.
How long before it means anything. The mechanism runs through angiogenesis and collagen deposition, and both take weeks. Granulation and perfusion changes are the first to appear; collagen remodeling in skin is a 6–12 week process. An improvement visible within 48 hours of an injection is the needle, the volume, or the hyaluronic acid it was mixed with — not the nucleotides. Judge at 8 weeks, not at 2 days.
What will fool you. Four things, all of them common. The injection trauma itself, which produces neocollagenesis without any drug. The co-injected hyaluronic acid, which produces immediate visible volume Araco 2023. Spontaneous healing, since most wounds and most tendinopathies improve given time. And the photograph, which changes with lighting, hydration and time of day more than most treatments do.
The blood half, which is small but not zero. If PDRN is being used on a wound that is not healing, the two measurements that most often explain the failure are HbA1c — because a wound in poorly controlled diabetes has a perfusion and immune problem no local agent will fix — and hs-CRP with a CBC, because an ulcer that is not healing is often infected. Those two draws will change management more often than the injection will.
What nobody has tested yet
Four experiments that would settle most of the argument about this product, none of which requires a new molecule.
Nobody has run PDRN against a saline injection control for an aesthetic endpoint. The needle is a confound and everyone knows it. A split-face design — nucleotides one side, saline the other, same needle, same operator, blinded assessor — is cheap, obvious, and absent. It would answer the central question about the entire category.
Nobody has compared source species or fragment sizes head to head. Products differ in origin and molecular weight distribution Kim 2021, and the A2A mechanism predicts that degradation rate — a function of fragment size — sets the duration of adenosine release. Two fragment-size ranges in the same wound model would test that directly and would give the field its first structure-activity relationship.
Nobody has tested it against a direct A2A agonist. If adenosine A2A signaling is the mechanism Galeano 2021, a selective A2A agonist should reproduce the effect, and any part it does not reproduce belongs to the salvage pathway. That single comparison would divide the two mechanisms cleanly and nobody has run it.
Nobody has surveyed what is in the products people actually buy. DNA quantification, agarose gel or capillary sizing, and protein contamination assays are undergraduate techniques. A survey of a dozen marketed products would establish whether the material matches the licensed pharmaceutical standard the clinical evidence was generated with, and it is the highest-value unglamorous experiment on this page.
PDRN — its own safety story, not its class's
The class block above is written for injectable repair compounds. Here is what is specific to a purified DNA extract.
The risk lives in the purification, not in the active ingredient. Vertebrate DNA itself is poorly immunogenic. Residual protein from the source tissue is not — and salmon protein is a recognized allergen. Anyone with a fish allergy has a specific and legitimate reason to avoid this, and it is a question about manufacturing quality rather than about pharmacology.
The second manufacturing risk is bacterial DNA and endotoxin. Unmethylated CpG motifs from bacterial contamination are TLR9 agonists and would turn an anti-inflammatory product into a pro-inflammatory one. Endotoxin limits are a routine pharmaceutical specification and are not something an end user can verify.
The mechanistic caution is the same one that applies to everything pro-angiogenic, and here it is local. A2A-driven VEGF expression Galeano 2021 means new vessel growth where the product is placed. That is the therapeutic effect in a wound and it is the reason not to inject it into or beside an undiagnosed lesion. Because the compound acts locally and is degraded locally, this concern is genuinely local — which makes it easier to manage than for a systemic agent, not less real.
The tolerability record is good and the reason is structural. The material is degraded to nucleosides the body already handles, and reported adverse effects are dominated by injection-site pain, transient swelling and bruising — the profile of the needle rather than of the substance Araco 2023.
The honest bottom line. A licensed pharmaceutical-grade polynucleotide injectable with a coherent receptor mechanism Galeano 2021, consistent animal data across soft tissue and bone Lim 2021, and a human literature that is mostly combination products without needle controls. The compound is more plausible than most things on this site and is less well tested than its marketing implies.
Sources read for this page
- Galeano M, et al. Polydeoxyribonucleotide: A Promising Biological Platform to Accelerate Impaired Skin Wound Healing. Pharmaceuticals (Basel) 2021 · PMID 34832885
- Kim TH, et al. Applications of Marine Organism-Derived Polydeoxyribonucleotide: Its Potential in Biomedical Engineering. Marine Drugs 2021 · PMID 34067499
- Araco A, Araco F. Clinical efficacy and safety of polynucleotides highly purified technology (PN-HPT) and cross-linked hyaluronic acid for moderate to severe nasolabial folds: A prospective, randomized, exploratory study. Journal of Cosmetic Dermatology 2023 · PMID 35531796
- Lim HK, et al. Bone regeneration in ceramic scaffolds with variable concentrations of PDRN and rhBMP-2. Scientific Reports 2021 · PMID 34075179
PDRN — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Repair peptides work by promoting angiogenesis — new blood vessel growth — plus fibroblast migration and growth-factor signaling. That is what makes them useful, and it is the entire basis of the one theoretical concern worth naming: angiogenesis is also what a tumor needs to grow beyond a few millimetres.
- There is no evidence these compounds cause or accelerate cancer. There is a mechanistic reason not to run a pro-angiogenic agent systemically with an active or recently treated malignancy, and that reasoning stands without a trial.
- The second predicted issue is more mundane and more likely: they can mask a signal. Something that reduces pain and inflammation around an injury lets you load a tissue that has not finished healing.
What has actually been reported
- Very well tolerated in reported use. Injection-site reactions and transient light-headedness are the common complaints.
- Human data is thin — most of the literature is rodent — so 'well tolerated' here means 'no signal has emerged from a lot of informal use', which is weaker than a clean trial and stronger than nothing.
How to reduce the risk
Same mechanism as the prediction.
- Stop when the thing you were treating has resolved. There is no mechanism here that demands a clock, and equally no reason to keep running a pro-angiogenic signal once the job is done.
- Do not let reduced pain set your training load. The tissue heals on its own timeline whether or not you can feel it. Reloading early on the strength of feeling better is the most common way people turn a good result into a re-injury.
- Get the diagnosis before the peptide. These accelerate healing of things that heal. A tear that needs surgical repair does not become a tear that does not, and the delay costs you.
- One injury, one compound, long enough to judge it. Otherwise you learn nothing transferable for next time.
What it does to your bloodwork
A fact about the assay.
- Nothing routine tracks these directly. The endpoint is the injury, which means your own honest assessment of function is the measurement.
Don't run this if
- Active or recently treated malignancy — the angiogenesis reasoning.
- Any undiagnosed lump or lesion. Find out what it is first.
The honest unknown
- Long-term systemic exposure in humans has never been characterized. The use case is naturally self-limiting — you stop when the injury resolves — which is why this matters less here than it would elsewhere.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
PDRN — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What PDRN moves on your bloodwork
Expected direction, not a measured one.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
If a repair peptide is doing anything systemic, inflammation is where it would plausibly show.
What to do: Worth a baseline if you are running one for a chronic issue rather than an acute injury. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Standard baseline. Nothing in this class predicts a specific abnormality — which is itself worth saying rather than inventing one.
What to do: Annual is fine unless something changes.
The honest position on this class is that the proliferation question is unresolved — anything that accelerates tissue repair is acting on pathways cancer also uses. Nobody has studied it properly either way.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- How the forms differ in dose
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — PDRN in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside PDRN
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Baseline inflammation — the thing you're claiming to reduce |
| Complete Blood Count (CBC) with Differential | Infection, anemia and platelet count before anything injectable |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney baseline |
| Vitamin D (25-Hydroxy) | Low D slows soft-tissue and bone healing measurably |
The Inflammation Deep Dive panel covers these in one order — 10 markers, $248.35 with the discount applied.
Check results you already have → · All 103 markers A–Z
PDRN — frequently asked questions
What is PDRN?
PDRN (Polydeoxyribonucleotide, polynucleotide (PN), 'salmon DNA') is a healing & recovery research compound. A mixture of purified DNA fragments (roughly 50–1,500 kDa) extracted from salmon or trout milt. Two mechanisms run in parallel, which is why it does more than a moisturizer. (1) Adenosine A2A receptor agonism — the fragments release adenosine-like signals that activate A2A, which upregulates VEGF, drives angiogenesis, and pushes macrophages from a pro-inflammatory toward a repair phenotype. (2) The salvage pathway — proliferating fibroblasts need purines and pyrimidines to build new DNA, and PDRN supplies them ready-made, so the cell spends less energy synthesizing nucleotides from scratch. The net result is fibroblast proliferation and collagen synthesis in tissue that is trying to rebuild.
Is the full PDRN protocol on this page?
The reported research dose is on this page, along with how PDRN works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of PDRN?
PDRN has an approximate half-life of Local depot; acts at the injection site rather than systemically, which is part of what determines how often it's dosed.
What forms does PDRN come in?
PDRN is available as: Injectable, Topical.
What's the evidence behind PDRN?
Current evidence level: Human RCTs for wound healing and diabetic foot ulcers; licensed as Placentex in Italy and widely used in Korean aesthetic practice. PDRN is offered for research purposes only and is not an approved medicine.
What PDRN is used for
PDRN appears under 2 goals in the goal router.
Related Healing & Recovery compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.